Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN)

Historical Holders from Q2 2017 to Q3 2025

Symbol
MRSN on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
4.99M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
55.4K
Holdings value
$411K
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
5
Number of sells
-78
Average Value change %
0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nextech Crossover I GP S.a r.l. 10.4% $4.34M 12.1M Nextech Crossover I GP S.a. r.l. 20 Dec 2024
VANGUARD GROUP INC 6.72% $3.02M 8.38M The Vanguard Group 31 Mar 2025
BlackRock, Inc. 3% -52.9% $1.1M -$1.34M 3.76M -54.8% BlackRock, Inc. 30 Jun 2025
Venrock Healthcare Capital Partners III, L.P. 2.9% -67.5% $1.29M -$2.41M 3.57M -65.2% Venrock Healthcare Capital Partners III, L.P. 31 Mar 2025
Schonfeld Strategic Advisors LLC 5.48% +18.6% $2.12M -$41.9M 274K -95.2% Schonfeld Strategic Advisors LLC 30 Sep 2025

Institutional Holders of Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 55.4K $411K -$31.5M $7.76 5
2025 Q2 77.2M $22.8M -$3.44M $0.30 80
2025 Q1 87.9M $30.3M -$35.8M $0.34 109
2024 Q4 104M $149M -$25M $1.43 129
2024 Q3 116M $219M +$3.27M $1.89 115
2024 Q2 114M $230M -$24M $2.01 120
2024 Q1 117M $526M +$24M $4.48 124
2023 Q4 113M $262M +$21M $2.32 104
2023 Q3 114M $144M -$76.6M $1.27 127
2023 Q2 112M $370M +$12.8M $3.29 145
2023 Q1 107M $437M +$17.7M $4.11 156
2022 Q4 101M $594M +$41.4M $5.86 150
2022 Q3 92.4M $625M +$39.1M $6.76 147
2022 Q2 88.3M $408M +$36.8M $4.62 121
2022 Q1 80.9M $323M +$33.1M $3.99 127
2021 Q4 70.2M $437M -$9.66M $6.22 120
2021 Q3 68.7M $648M -$40.8M $9.43 108
2021 Q2 69.8M $947M -$9.19M $13.58 129
2021 Q1 68.2M $1.1B -$36.2M $16.18 130
2020 Q4 68.1M $1.81B +$51.9M $26.61 147
2020 Q3 67.9M $1.26B +$48.6M $18.62 132
2020 Q2 64.7M $1.51B +$685M $23.40 129
2020 Q1 40.1M $234M +$26.1M $5.83 82
2019 Q4 35.5M $203M -$6M $5.73 69
2019 Q3 38.5M $60.8M -$6.78M $1.58 73
2019 Q2 40M $162M +$12M $4.05 77
2019 Q1 36.9M $194M +$105M $5.26 65
2018 Q4 17.2M $70M -$10.2M $4.08 48
2018 Q3 19.8M $198M +$76.4K $10.00 46
2018 Q2 19.1M $342M +$7.61M $17.86 52
2018 Q1 18.7M $295M +$23.7M $15.77 56
2017 Q4 15.5M $254M -$4.02M $16.43 45
2017 Q3 15.7M $271M +$10.6M $17.29 40
2017 Q2 17M $236M +$236M $13.97 29